Product image of Ifirmacombi (Hydrochlorothiazide, Irbesartan) supplied by GNH India

Ifirmacombi

Active Ingredient:
Hydrochlorothiazide, Irbesartan
Origin:
EU

Ifirmacombi (Hydrochlorothiazide, Irbesartan)

Hydrochlorothiazide and Irbesartan, the active ingredients in Ifirmacombi, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for oral use. They treat hypertension in adult patients by lowering blood pressure through complementary mechanisms.

GNH India supplies Ifirmacombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ifirmacombi is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

  • Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension.
  • Cardiovascular risk reduction: helps lower the risk of stroke and myocardial infarction associated with uncontrolled blood pressure.
  • Combination therapy: provides synergistic blood‑pressure control when a diuretic and an ARB are required together.

How It Works

  • Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting sodium and water excretion. The combined actions decrease peripheral vascular resistance and plasma volume, resulting in lowered arterial pressure.

Side Effects

Ifirmacombi may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects

  • Dizziness: feeling light‑headed, especially after standing.
  • Headache: mild to moderate intensity.
  • Increased urination: due to the diuretic component.
  • Electrolyte imbalance: low potassium or sodium levels.
  • Fatigue: general tiredness.
  • Dry mouth: reduced salivation.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Hyperkalemia: dangerously high potassium levels.
  • Severe hyponatremia: markedly low sodium concentration.
  • Acute kidney injury: sudden decline in renal function.
  • Pancreatitis: inflammation of the pancreas.
  • Blood dyscrasias: abnormal blood cell counts.

Precautions & Warnings

Before initiating Ifirmacombi, clinicians should assess patient history and monitor relevant parameters.

  • Blood pressure monitoring: ensure target levels are achieved without excessive drop.
  • Electrolyte assessment: check potassium and sodium regularly.
  • Renal function evaluation: monitor serum creatinine and eGFR.
  • Caution in diabetes: watch for changes in glucose control.
  • Avoid in severe hepatic impairment: limited data support safe use.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ifirmacombi can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Aliskiren: combined renin‑angiotensin blockade may cause renal dysfunction.
  • Potassium‑sparing diuretics: risk of hyperkalemia.
  • NSAIDs: may blunt antihypertensive effect and impair renal function.
  • Lithium: increased lithium toxicity.
  • ACE inhibitors: additive risk of hyperkalemia.

Moderate Interactions (Monitor Closely)

  • Other diuretics: may cause excessive hypotension.
  • Antihypertensives: additive blood‑pressure lowering.
  • Antacids containing aluminum or magnesium: may reduce absorption of irbesartan.
  • CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan levels.
  • Digoxin: altered potassium may affect digoxin toxicity.

Frequently Asked Questions

Ifirmacombi is a prescription medication that combines hydrochlorothiazide and irbesartan to treat hypertension. The two components work together to lower blood pressure by reducing fluid volume and blocking vasoconstrictive signals, helping patients achieve target blood‑pressure goals.

Irbesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urinary excretion of water and salts. The dual action decreases both vascular resistance and plasma volume, resulting in lower arterial pressure.

The appropriate dose of Ifirmacombi is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the regimen on their own.

Safety data for Ifirmacombi in pregnancy and lactation are limited. Generally, angiotensin‑II receptor blockers are avoided during the second and third trimesters because of potential fetal harm, and the diuretic component may affect fluid balance. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ifirmacombi offers a fixed‑dose combination of a thiazide diuretic and an ARB, which can simplify therapy compared with taking separate agents. Compared with ACE‑inhibitor + diuretic combos, it may have a lower incidence of cough and similar blood‑pressure efficacy, while providing the renal‑protective benefits of an ARB.

Ifirmacombi tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Ifirmacombi is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe allergic reactions (anaphylaxis), hyperkalemia, acute kidney injury, and marked electrolyte disturbances such as hyponatremia. Patients should be educated to seek immediate medical attention if they experience swelling, difficulty breathing, muscle weakness, or sudden changes in urine output.

Ifirmacombi is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, or those taking aliskiren in combination with an ACE inhibitor or ARB. Caution is also advised for individuals with severe hepatic disease, uncontrolled diabetes, or electrolyte abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT